Innovative Business Models Will Take Center Stage at the PharmAsia Summit-Shanghai

Shanghai, April 12, 2012 – Most biopharma executives agree that the current model for innovation is broken. From declining R&D productivity, to demands from payers to show real-world value, to the much publicized patent cliff, the industry faces unprecedented challenges that require fundamental changes across the entire value chain.

To discuss these strategic challenges and potential solutions for renewed growth, Elsevier Business Intelligence and The BayHelix Group invite you to attend the 3rd PharmAsia Summit, to be held September 24 - 26, 2012, in Shanghai.

“Our location in Shanghai – the center of China’s pharma industry – is no accident,” said Jimmy Zhang, Chairman BayHelix. “China, and other major emerging markets, provides a real-world laboratory to experiment with new models of innovation across the entire value chain, nurtured by a climate less encumbered by legacy systems or engrained mindsets.”

Indeed, the rise of emerging markets has provided multinationals with significant new growth opportunities and cash flow – but also the challenge to achieve better health outcomes in regions struggling with affordability barriers and huge unmet medical needs.

Given the scope of challenges, there is a sense of urgency and government focus in emerging markets, creating a ripe environment for companies to test new R&D and business models in collaboration with industry peers, governments, payers, academia, contract research organizations, healthcare professionals and other key stakeholders.

“These new models, tested in emerging markets, could also help drive fundamental change in established markets like the U.S. and Europe, creating opportunities to reshape the biopharma industry for the 21st Century,” said Gerry Stoia, President of Elsevier Business Intelligence.

At the PharmAsia Summit-Shanghai, Elsevier and BayHelix will feature data and case studies from China, India and other emerging markets focusing on two key imperatives of innovation: (1) Getting Better Products To Market Faster; and (2) Creating Value For Patients And Payers. Summit attendees can also get a firsthand look at innovation in China by opting to tour a local science and technology park as part of a special conference delegation.

To kick off the Summit, Elsevier, BayHelix and the Monitor Group will release an exclusive report exploring how China could disrupt the innovation paradigm, based on an industry survey and discussions with key corporate leaders and policy makers.

The program for this year’s Summit has been created by an advisory board chaired by Steve Yang, VP, Head of R&D for Asia & Emerging Markets, AstraZeneca PLC.

For further information, visit: To participate in the industry survey (which includes a 15% discount to attend the PharmAsia Summit-Shanghai) visit:

# # #

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and “The Pink Sheet.” For more information, visit:

About BayHelix Group
BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit:

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contacts
Joshua L. Berlin
Elsevier Business Intelligence
+1 301 538 3527

Tony Zhang
+86 21 5197 0606